Plasminogen activator response after DDAVP: A clinico-pharmacological study

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

This study evaluates how plasminogen activator (PA) behaves in response to intravenous (i.v.) and intranasal (i.n.) DDAVP in healthy subjects. Five volunteers received in random order four i.v. DDAVP doses (0.1-0.4 μg/Kg) and saline. Changes in PA (euglobulin lysis time) were measured from baseline after 30, 120 and 360 min. PA increased significantly with dose and reached a seven-fold mean rise at 0.4 μg/Kg. Five other subjects, similarly treated with i.n. DDAVP (1-4 μg/Kg), showed a significant increase (two-fold over baseline values) but no clear dose-response relationship. To evaluate the rate of PA return to baseline values, seven subjects received a single i.v. DDAVP dose (0.4 μg/Kg) and PA changes were measured at various post-infusion intervals. The pattern of PA clearance from the circulation was clearly bimodal. The mean half-disappearance time of the rapid component was 62 min, that of the slower component, 457 min. Finally, to assess the consistency of PA response following repeated treatment, five healthy subjects were given five daily i.v. doses of DDAVP (0.4 μg/Kg). Even though there was a progressive reduction in the response, a significant increase over baseline was still observed after the last dose.

Original languageEnglish
Pages (from-to)69-76
Number of pages8
JournalThrombosis Research
Volume20
Issue number1
Publication statusPublished - 1980

Fingerprint

Deamino Arginine Vasopressin
Plasminogen Activators
Pharmacology
Healthy Volunteers
Fibrin Clot Lysis Time
Volunteers

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Hematology

Cite this

Plasminogen activator response after DDAVP : A clinico-pharmacological study. / Mannucci, P. M.; Rota, L.

In: Thrombosis Research, Vol. 20, No. 1, 1980, p. 69-76.

Research output: Contribution to journalArticle

@article{79391dcdae6147c4a2ef9d9877471ffd,
title = "Plasminogen activator response after DDAVP: A clinico-pharmacological study",
abstract = "This study evaluates how plasminogen activator (PA) behaves in response to intravenous (i.v.) and intranasal (i.n.) DDAVP in healthy subjects. Five volunteers received in random order four i.v. DDAVP doses (0.1-0.4 μg/Kg) and saline. Changes in PA (euglobulin lysis time) were measured from baseline after 30, 120 and 360 min. PA increased significantly with dose and reached a seven-fold mean rise at 0.4 μg/Kg. Five other subjects, similarly treated with i.n. DDAVP (1-4 μg/Kg), showed a significant increase (two-fold over baseline values) but no clear dose-response relationship. To evaluate the rate of PA return to baseline values, seven subjects received a single i.v. DDAVP dose (0.4 μg/Kg) and PA changes were measured at various post-infusion intervals. The pattern of PA clearance from the circulation was clearly bimodal. The mean half-disappearance time of the rapid component was 62 min, that of the slower component, 457 min. Finally, to assess the consistency of PA response following repeated treatment, five healthy subjects were given five daily i.v. doses of DDAVP (0.4 μg/Kg). Even though there was a progressive reduction in the response, a significant increase over baseline was still observed after the last dose.",
author = "Mannucci, {P. M.} and L. Rota",
year = "1980",
language = "English",
volume = "20",
pages = "69--76",
journal = "Thrombosis Research",
issn = "0049-3848",
publisher = "Elsevier Limited",
number = "1",

}

TY - JOUR

T1 - Plasminogen activator response after DDAVP

T2 - A clinico-pharmacological study

AU - Mannucci, P. M.

AU - Rota, L.

PY - 1980

Y1 - 1980

N2 - This study evaluates how plasminogen activator (PA) behaves in response to intravenous (i.v.) and intranasal (i.n.) DDAVP in healthy subjects. Five volunteers received in random order four i.v. DDAVP doses (0.1-0.4 μg/Kg) and saline. Changes in PA (euglobulin lysis time) were measured from baseline after 30, 120 and 360 min. PA increased significantly with dose and reached a seven-fold mean rise at 0.4 μg/Kg. Five other subjects, similarly treated with i.n. DDAVP (1-4 μg/Kg), showed a significant increase (two-fold over baseline values) but no clear dose-response relationship. To evaluate the rate of PA return to baseline values, seven subjects received a single i.v. DDAVP dose (0.4 μg/Kg) and PA changes were measured at various post-infusion intervals. The pattern of PA clearance from the circulation was clearly bimodal. The mean half-disappearance time of the rapid component was 62 min, that of the slower component, 457 min. Finally, to assess the consistency of PA response following repeated treatment, five healthy subjects were given five daily i.v. doses of DDAVP (0.4 μg/Kg). Even though there was a progressive reduction in the response, a significant increase over baseline was still observed after the last dose.

AB - This study evaluates how plasminogen activator (PA) behaves in response to intravenous (i.v.) and intranasal (i.n.) DDAVP in healthy subjects. Five volunteers received in random order four i.v. DDAVP doses (0.1-0.4 μg/Kg) and saline. Changes in PA (euglobulin lysis time) were measured from baseline after 30, 120 and 360 min. PA increased significantly with dose and reached a seven-fold mean rise at 0.4 μg/Kg. Five other subjects, similarly treated with i.n. DDAVP (1-4 μg/Kg), showed a significant increase (two-fold over baseline values) but no clear dose-response relationship. To evaluate the rate of PA return to baseline values, seven subjects received a single i.v. DDAVP dose (0.4 μg/Kg) and PA changes were measured at various post-infusion intervals. The pattern of PA clearance from the circulation was clearly bimodal. The mean half-disappearance time of the rapid component was 62 min, that of the slower component, 457 min. Finally, to assess the consistency of PA response following repeated treatment, five healthy subjects were given five daily i.v. doses of DDAVP (0.4 μg/Kg). Even though there was a progressive reduction in the response, a significant increase over baseline was still observed after the last dose.

UR - http://www.scopus.com/inward/record.url?scp=0019215882&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019215882&partnerID=8YFLogxK

M3 - Article

C2 - 7193918

AN - SCOPUS:0019215882

VL - 20

SP - 69

EP - 76

JO - Thrombosis Research

JF - Thrombosis Research

SN - 0049-3848

IS - 1

ER -